Univariate and multivariate analyses of the prognostic factors associated with PFS and OS in the 5′RACE cohort from the PMBL LYSA cohort
| PFS . | n . | Univariate analysis . | Multivariate analysis . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | n . | HR (95% CI) . | P value . | ||
| Treatment (ref = R-ACVBP) | ||||||
| R-CHOP14 | 65 | Infinite | ||||
| R-CHOP21 | 64 | 1 (0.12-8.4) | 1 | |||
| LDH greater than ULN | 75 | 0.52 (0.1-2.7) | .43 | |||
| IPI 3-5 | 75 | 2.1 (0.47-9.7) | .32 | |||
| MTV ≥360 cm3 | 60 | 2.8 (0.47-17) | .26 | |||
| PDL1high/PDL2high | 75 | 1.7 (0.38-7.8) | .48 | |||
| HCD (>81.1% and >78.6% of all CDR3 sequences for IgVH and IgVL, 5′RACE) | 75 | 17 (3.2-88) | .00087 | 75 | 14.6 (2.46-86.8) | .00317 |
| IgVH clonal dominance (continuous variable, 5′RACE) | 75 | 1 (1-1.1) | .034 | |||
| IgVL clonal dominance (continuous variable, 5′RACE) | 75 | 1 (0.99-1.1) | .15 | |||
| Highest IgVH clonal dominance (>81.1% of all CDR3 sequences for IgVH, 5′RACE) | 75 | 9.9 (1.9-51) | .0065 | |||
| Highest IgVL clonal dominance (>78.6% of all CDR3 sequences for IgVL, 5′RACE) | 75 | 5.2 (1-27) | .05 | |||
| AID gene expression | 75 | 1.2 (1-1.3) | .032 | 75 | 1.04 (0.88-1.2) | .6563 |
| AID gene expression greater than median | 75 | 6.1 (0.73-51) | .095 | |||
| Proportion of tumoral infiltration (histology) | 74 | 1 (0.95-1.06) | .86 | |||
| OS | n | Univariate analysis | Multivariate analysis | |||
| HR (95% CI) | Pvalue | n | HR (95% CI) | Pvalue | ||
| Treatment (ref = R-ACVBP) | ||||||
| R-CHOP14 | 65 | Infinite | ||||
| R-CHOP21 | 64 | 2 (0.2-19) | .56 | |||
| LDH greater than ULN | 75 | 0.63 (0.065-6.1) | .69 | |||
| IPI 3-5 | 75 | 2.5 (0.35-18) | .36 | |||
| MTV ≥360 cm3 | 60 | Infinite | ||||
| PDL1high/PDL2high | 75 | 2.1 (0.3-15) | .45 | |||
| HCD (>81.1% and >78.6% of all CDR3 sequences for IgVH and IgVL, 5′RACE) | 75 | 21 (2.1-210) | .0094 | 75 | 11.4 (1-128.8) | .0496 |
| IgVH clonal dominance (continuous variable, 5′RACE) | 75 | 1 (0.99-1.1) | .09 | |||
| IgVL clonal dominance (continuous variable, 5′RACE) | 75 | 1 (0.98-1.1) | .32 | |||
| Highest IgVH clonal dominance (>81.1% of all CDR3 sequences for IgVH, 5′RACE) | 75 | 13 (1.3-120) | .03 | |||
| Highest IgVL clonal dominance (>78.6% of all CDR3 sequences for IgVL, 5′RACE) | 75 | 6.5 (0.67-62) | .11 | |||
| AID gene expression | 75 | 1.3 (1.1-1.5) | .0067 | 75 | 1.2 (1-1.5) | .1467 |
| AID gene expression greater than median | 75 | Infinite | ||||
| Proportion of tumoral infiltration (histology) | 74 | 1 (0.93-1.07) | .9 | |||
| PFS . | n . | Univariate analysis . | Multivariate analysis . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | n . | HR (95% CI) . | P value . | ||
| Treatment (ref = R-ACVBP) | ||||||
| R-CHOP14 | 65 | Infinite | ||||
| R-CHOP21 | 64 | 1 (0.12-8.4) | 1 | |||
| LDH greater than ULN | 75 | 0.52 (0.1-2.7) | .43 | |||
| IPI 3-5 | 75 | 2.1 (0.47-9.7) | .32 | |||
| MTV ≥360 cm3 | 60 | 2.8 (0.47-17) | .26 | |||
| PDL1high/PDL2high | 75 | 1.7 (0.38-7.8) | .48 | |||
| HCD (>81.1% and >78.6% of all CDR3 sequences for IgVH and IgVL, 5′RACE) | 75 | 17 (3.2-88) | .00087 | 75 | 14.6 (2.46-86.8) | .00317 |
| IgVH clonal dominance (continuous variable, 5′RACE) | 75 | 1 (1-1.1) | .034 | |||
| IgVL clonal dominance (continuous variable, 5′RACE) | 75 | 1 (0.99-1.1) | .15 | |||
| Highest IgVH clonal dominance (>81.1% of all CDR3 sequences for IgVH, 5′RACE) | 75 | 9.9 (1.9-51) | .0065 | |||
| Highest IgVL clonal dominance (>78.6% of all CDR3 sequences for IgVL, 5′RACE) | 75 | 5.2 (1-27) | .05 | |||
| AID gene expression | 75 | 1.2 (1-1.3) | .032 | 75 | 1.04 (0.88-1.2) | .6563 |
| AID gene expression greater than median | 75 | 6.1 (0.73-51) | .095 | |||
| Proportion of tumoral infiltration (histology) | 74 | 1 (0.95-1.06) | .86 | |||
| OS | n | Univariate analysis | Multivariate analysis | |||
| HR (95% CI) | Pvalue | n | HR (95% CI) | Pvalue | ||
| Treatment (ref = R-ACVBP) | ||||||
| R-CHOP14 | 65 | Infinite | ||||
| R-CHOP21 | 64 | 2 (0.2-19) | .56 | |||
| LDH greater than ULN | 75 | 0.63 (0.065-6.1) | .69 | |||
| IPI 3-5 | 75 | 2.5 (0.35-18) | .36 | |||
| MTV ≥360 cm3 | 60 | Infinite | ||||
| PDL1high/PDL2high | 75 | 2.1 (0.3-15) | .45 | |||
| HCD (>81.1% and >78.6% of all CDR3 sequences for IgVH and IgVL, 5′RACE) | 75 | 21 (2.1-210) | .0094 | 75 | 11.4 (1-128.8) | .0496 |
| IgVH clonal dominance (continuous variable, 5′RACE) | 75 | 1 (0.99-1.1) | .09 | |||
| IgVL clonal dominance (continuous variable, 5′RACE) | 75 | 1 (0.98-1.1) | .32 | |||
| Highest IgVH clonal dominance (>81.1% of all CDR3 sequences for IgVH, 5′RACE) | 75 | 13 (1.3-120) | .03 | |||
| Highest IgVL clonal dominance (>78.6% of all CDR3 sequences for IgVL, 5′RACE) | 75 | 6.5 (0.67-62) | .11 | |||
| AID gene expression | 75 | 1.3 (1.1-1.5) | .0067 | 75 | 1.2 (1-1.5) | .1467 |
| AID gene expression greater than median | 75 | Infinite | ||||
| Proportion of tumoral infiltration (histology) | 74 | 1 (0.93-1.07) | .9 | |||
HR was infinite when no deaths occurred in the selected subgroup. Multivariate analysis was performed with selected relevant variables that were most significantly associated with PFS or OS in the univariate analysis. Bold values indicate that statistical significance was reached (P < .05).
IPI, International Prognostic Index; LDH, lactate dehydrogenase; ref, reference; ULN, upper limit of normal laboratory value.